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Autism spectrum disorders (ASDs) are a heterogeneous group of neurodevelopmental
disorders that are defined solely on the basis of behavioral observations. Therefore, ASD
has traditionally been framed as a behavioral disorder. However, evidence is accumulating
that ASD is characterized by certain physiological abnormalities, including oxidative
stress, mitochondrial dysfunction and immune dysregulation/inflammation. While these
abnormalities have been reported in studies that have examined peripheral biomarkers
such as blood and urine, more recent studies have also reported these abnormalities
in brain tissue derived from individuals diagnosed with ASD as compared to brain
tissue derived from control individuals. A majority of these brain tissue studies have
been published since 2010. The brain regions found to contain these physiological
abnormalities in individuals with ASD are involved in speech and auditory processing,
social behavior, memory, and sensory and motor coordination. This manuscript
examines the evidence linking oxidative stress, mitochondrial dysfunction and immune
dysregulation/inflammation in the brain of ASD individuals, suggesting that ASD has a
clear biological basis with features of known medical disorders. This understanding may
lead to new testing and treatment strategies in individuals with ASD.
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INTRODUCTION
Autism spectrum disorders (ASD) are a group of neurodevel-
opmental disorders that are defined by behavioral observations
including communication and social interaction problems and
repetitive behaviors (APA, 1994). ASD affects an estimated 1 out
of 88 individuals in the United States (U.S.) (Baio, 2012) with
four times more males than females being affected (Rice, 2007).
The etiology of ASD is unclear at this time. Although several
genetic syndromes, including Fragile X and Rett syndrome, have
been associated with ASD; genetic defects account for only a small
percentage of ASD cases (Schaefer et al., 2013).
Although many of the cognitive and behavioral features of
ASD are thought to arise from dysfunction of the brain, evidence
from many fields of medicine has documented physiological
abnormalities in organs besides the brain that are associated with
ASD, suggesting that, in some individuals, ASD arises from sys-
temic, rather than organ specific abnormalities (Rossignol and
Frye, 2012a). Specifically, in recent decades, research and clini-
cal studies have implicated physiological and metabolic systems
that transcend specific organ dysfunction, such as immune dys-
regulation and inflammation, abnormalities in redox regulation
and oxidative stress, and dysfunction of energy generation and
mitochondrial systems (Ming et al., 2008; Rossignol and Frye,
2012a). In this context, ASD may arise from, or at least involve,
systemic physiological abnormalities rather than being a purely
central nervous system (CNS) disorder (Herbert, 2005), at least
in a subset of individuals with ASD. However, because the CNS
is affected in ASD, examining physiological abnormalities in the
brain may reveal more about what is abnormal than inspecting
abnormalities in blood or urine samples.
A number of studies have reported evidence of oxidative stress
in individuals with ASD (Yorbik et al., 2002; James et al., 2004,
2006, 2009a,b; Ming et al., 2005; Chauhan and Chauhan, 2006;
Yao et al., 2006; Al-Gadani et al., 2009; Melnyk et al., 2012; Rose
et al., 2012a; Rossignol and Frye, 2012a) and their parents (James
et al., 2008). Genetic variations in glutathione-related pathways
have been observed in ASD (Boris et al., 2004; James et al., 2006;
Bowers et al., 2011; Frustaci et al., 2012) and have been corre-
lated in some studies with ASD behaviors (Goin-Kochel et al.,
2009; Guo et al., 2012). Several case-control studies have reported
lower concentrations of reduced glutathione (GSH), higher levels
of oxidized glutathione (GSSG) and a decrease in the GSH/GSSG
redox ratio (James et al., 2004, 2006, 2009b), along with a lower
mitochondrial GSH reserve (James et al., 2009a) in individuals
with ASD compared to controls. In addition, in some studies,
lower GSH levels (Adams et al., 2009) and markers of increased
oxidative stress (Ghezzo et al., 2013) have been correlated with
ASD severity. Markers of oxidative stress have also been correlated
with the severity of gastrointestinal problems in ASD individuals
(Gorrindo et al., 2013). Notably, these aforementioned stud-
ies examined peripheral markers of oxidative stress, including
those found in blood and urine. Recently, a number of studies
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have reported evidence of oxidative stress in post-mortem brain
samples from individuals with ASD compared to controls (Evans
et al., 2008; López-Hurtado and Prieto, 2008; Sajdel-Sulkowska
et al., 2008, 2009; Palmieri et al., 2010; Chauhan et al., 2011;
Sajdel-Sulkowska et al., 2011; Chauhan et al., 2012a; Rose et al.,
2012b; Gu et al., 2013a,b; Tang et al., 2013).
Multiple studies have also reported evidence of mitochondrial
dysfunction in individuals with ASD (Rossignol and Bradstreet,
2008; Weissman et al., 2008; Giulivi et al., 2010; Guevara-Campos
et al., 2010; Shoffner et al., 2010; Zhang et al., 2010; Dhillon
et al., 2011; Frye and Rossignol, 2011; Chauhan et al., 2012b; Frye,
2012; Frye and Rossignol, 2012a; Rossignol and Frye, 2012a,b;
Frye et al., 2013a,b; Frye and Rossignol, 2013). In some studies,
biomarkers of mitochondrial dysfunction have been associated
with autistic behaviors or autism severity (Minshew et al., 1993;
Mostafa et al., 2005). One systematic review reported that over
30% of children with ASD have biomarkers of abnormal mito-
chondrial function suggesting that a relatively high percentage of
individuals with ASD might have some degree of mitochondrial
dysfunction (Rossignol and Frye, 2012b). Another study reported
that up to 50% of children with ASD have biomarkers of mito-
chondrial dysfunction that are valid (that is, they correlate with
other biomarkers of mitochondrial dysfunction) and are consis-
tently abnormal (that is, they are repeatedly abnormal) (Frye,
2012). However, like the studies on oxidative stress and ASD,most
of the published literature concerning mitochondrial dysfunc-
tion has examined blood and urine samples. A number of studies
recently have reported evidence of mitochondrial dysfunction in
ASD brain samples compared to controls (Palmieri et al., 2010;
Chauhan et al., 2011; Anitha et al., 2012, 2013; Ginsberg et al.,
2012; Rose et al., 2012b; Tang et al., 2013).
Finally, a number of studies have reported evidence of immune
dysregulation and/or inflammation in individuals with ASD
(Gupta et al., 2010; Onore et al., 2012; Rossignol and Frye, 2012a;
Depino, 2013; Gesundheit et al., 2013; Goines and Ashwood,
2013), including gene changes pertaining to the immune sys-
tem (Michel et al., 2012; Poultney et al., 2013). In some studies,
biomarkers of inflammation or immune dysregulation have been
correlated with ASD severity (Mostafa and Kitchener, 2009; Al-
Ayadhi and Mostafa, 2011, 2012, 2013; Khakzad et al., 2012;
Mostafa and Al-Ayadhi, 2012) and an elevation in TNF-alpha has
been reported in ASD lymphocytes (Malik et al., 2011a) and in
amniotic fluid in children who develop autism (Abdallah et al.,
2013). Particular interest surrounds elevations found in autoan-
tibodies to brain elements and other important molecular targets
such as the folate receptor autoantibody (Connolly et al., 1999;
Rossignol and Frye, 2012a; Frye et al., 2013c). Although there
have been a large number of studies examining immune abnor-
malities in ASD, almost all of these studies have examined blood
and urine samples. However, some studies have recently reported
evidence of brain-related immune dysregulation or inflammation
in ASD compared to controls (Vargas et al., 2005; Chez et al.,
2007; Garbett et al., 2008; Li et al., 2009; Morgan et al., 2010; Wei
et al., 2011; Young et al., 2011; Rose et al., 2012b; Suzuki et al.,
2013).
Recently, an interrelationship between oxidative stress, mito-
chondrial dysfunction, and/or inflammation has been reported in
some individuals with autism (James et al., 2009a; Mostafa et al.,
2010; Zhang et al., 2010; Rose et al., 2012b; Frye et al., 2013a;
Napoli et al., 2013; Theoharides et al., 2013). In this manuscript,
we concentrate on studies that have documented these physio-
logical abnormalities specifically in the CNS of individuals with
ASD. Reviewing the evidence for these physiological abnormali-
ties specifically in the CNS is important for several reasons. Firstly,
the CNS is protected from the rest of the body by the blood-
brain barrier. Although there is evidence that these physiological
abnormalities are present in non-CNS tissue in individuals with
ASD, it does not necessarily mean that they are present in the
CNS. Demonstrating that these abnormalities also affect the brain
would suggest that brain dysfunction in individuals with ASD is
not necessarily only secondary to systematic abnormalities, but
that the same abnormalities that influence peripheral organs also
directly influence brain function. Secondly, there are particular
patterns of abnormalities in the CNS that are associated with
ASD. Indeed, abnormalities in ASD have been reported in the
frontal and temporal cortices, the hippocampus and amygdala as
well as the cerebellum. Determining whether these physiological
abnormalities are also present in these brain areas would provide
insight into whether they could be involved in the pathological
mechanisms that result in ASD. Thus, this manuscript reviews
the evidence for oxidative stress, mitochondrial dysfunction and
immune dysregulation/inflammation in the brains of individuals
with ASD compared to controls as well as the evidence linking
these abnormalities.
STUDIES OF OXIDATIVE STRESS IN THE ASD BRAIN
A number of studies have reported evidence of oxidative stress in
post-mortem brain samples obtained from individuals with ASD
compared to controls (Table 1). These studies have demonstrated
a decrease in GSH, the major cellular antioxidant, oxidative dam-
age to proteins, lipids and deoxyribonucleic acid (DNA) as well
as alternations in the activity of enzymes important in redox
metabolism.
Several studies have reported GSH abnormalities in the brain
tissue of individuals with ASD. In one study of 10 individu-
als with autism and 10 age-matched controls, GSH/GSSG and
reduced GSH levels were both significantly lower in the cere-
bellum and temporal cortex in the autism group compared to
controls (Chauhan et al., 2012a). Another study of 15 individ-
uals with autism and 15 controls reported significantly lower
GSH and GSH/GSSG levels in the cerebellum and Brodmann area
22 (BA22) in the autism group. Interestingly, these markers of
GSH metabolism did not correlate with age, suggesting that the
oxidative stress observed was a chronic condition (Rose et al.,
2012b).
Enzymes important for redox metabolism have also been
found to be altered in brain tissue derived from individuals with
autism. In a study of temporal lobe brain samples (BA21) taken
from 20 individuals with autism and 25 controls, Tang et al.
observed a decrease in superoxide dismutase 2 activity in brain
samples from the autism group (Tang et al., 2013). Activities of
glutathione peroxidase, glutathione-S-transferase, and glutamate
cysteine ligase were each significantly decreased in the cerebel-
lum of the brains of 10 individuals with autism compared to
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Table 1 | Studies of oxidative stress in the ASD brain.
Year Citation No. of No. of Major findings
published ASD controls
2008 Evans et al., 2008 5 5 Increase in 3 oxidative damage markers in cerebellum, hippocampus and BA39 in
ASD group
2008 López-Hurtado and Prieto, 2008 8 7 Increase in lipofuscin containing cells in BA22, BA44, and BA39 in ASD group
2008 Sajdel-Sulkowska et al., 2008 9 10 Significant elevation in 3NT in ASD group; 3NT correlated with cerebellar mercury
concentration
2009 Sajdel-Sulkowska et al., 2009 8 7 3NT correlated with neurotrophin-3 in the ASD brain; 8-hydroxydeoxyguanosine
higher in cerebellum in ASD group
2010 Palmieri et al., 2010 6 6 Three-fold higher oxidative damage to mitochondrial proteins in BA41/42 or BA22
in ASD group
2011 Chauhan et al., 2011 8 8 Increased lipid hydroperoxides in temporal lobes and cerebellum in ASD group
2011 Sajdel-Sulkowska et al., 2011 2 2 Elevated 3NT in orbitofrontal cortex, Wernicke’s area, cerebellar vermis and pons
in ASD group
2012 Chauhan et al., 2012a 10 10 GSH/GSSG and reduced GSH levels both significantly lower in cerebellum and
temporal lobes in ASD group
2012 Rose et al., 2012b 15 15 GSH/GSSG and GSH both significantly lower in cerebellum and BA22 in ASD
group; 3NT elevated in cerebellum and BA22 in ASD group; 8-oxo-deoxyguanosine
elevated in cerebellum and BA22 in ASD group and correlated with GSH/GSSG
2013 Gu et al., 2013b 10 10 Glutathione peroxidase, Glutathione-S-transferase, glutamate cysteine ligase
decreased in cerebellum in ASD group
2013 Muratore et al., 2013 10 10 Similar 8-hydroxyguanosine in the frontal cortex (BA 9, 22, 41, 42, or 46) between
groups. Significantly lower methionine synthase mRNA along with lower levels of
homocysteine and cystathionine in these same areas in the autism brains
compared to controls, suggestive of adaptive responses to oxidative stress
2013 Tang et al., 2013 20 25 Diminished superoxide dismutase 2 activity in BA21 in ASD group;
8-oxo-deoxyguanosine higher in temporal lobe in ASD group
10 controls as reported by Gu et al. (2013b). Finally, signifi-
cantly lower methionine synthase mRNA along with lower levels
of homocysteine and cystathionine were observed in the frontal
cortex (BA 9, 22, 41, 42, or 46) in the brains of 10 individuals
with autism (ages 4–30 years) compared to 10 age- and sex-
matched controls, suggestive of adaptive responses to oxidative
stress (Muratore et al., 2013).
Some studies have reported oxidative damage to brain lipids
in ASD. One of the first studies reported a significant increase
in lipofuscin containing cells, a marker of oxidative stress, in 3
language areas of the brain (BA 22, 39, and 44) in 8 males with
autism compared to 7 male controls (López-Hurtado and Prieto,
2008). Another study reported significant immunoreactivity to
3 markers of oxidative damage (carboxyethyl pyrrole (CEP) and
iso[4]levuglandin (iso[4]LG)E2-protein adducts as well as heme
oxygenase-1) in cerebellar, hippocampal, and BA39 brain samples
from 5 subjects with autism but not in any of 5 controls (Evans
et al., 2008). Finally, one study of 8 children with autism and
8 controls reported significantly higher levels of lipid hydroper-
oxides (an oxidative stress marker) in the temporal cortex and
cerebellum in the autism group; mitochondrial dysfunction was
also observed in this study in the same areas (Chauhan et al.,
2011).
Other studies have documented significant oxidation of pro-
teins in brain tissue by examining levels of 3-nitrotyrosine
(3NT). One study which examined brain tissue from 9 indi-
viduals with autism and 10 controls reported that 3NT in the
cerebellum was significantly elevated in the autism group and was
significantly correlated (r = 0.80) with cerebellar mercury lev-
els (Sajdel-Sulkowska et al., 2008). In a follow-up study, these
investigators found that neurotrophin-3, a neurotrophin criti-
cal for normal brain growth and differentiation, was positively
correlated (r = 0.83) with 3NT in the cerebellum samples from
8 individuals with ASD compared to 7 controls. The investigators
suggested that increased neurotrophin-3 could affect brain devel-
opment and growth and lead to cerebellar overgrowth, and that
this increase in neurotrophin-3 could be due to increased lev-
els of oxidative stress in the developing brain (Sajdel-Sulkowska
et al., 2009). The same group examined 2 children with autism
and 2 age-matched controls and reported that 3NT varied widely
in the autism brain samples compared to a uniformly low level
in the control brains; the elevated levels of 3NT in the two
autism cases were found in areas of the brain responsible for sen-
sory and motor coordination, speech processing, memory and
social behavior (orbitofrontal cortex, Wernicke’s area, cerebel-
lar vermis and pons) (Sajdel-Sulkowska et al., 2011). A recent
study of 15 individuals with autism and 15 controls reported
a significant elevation of 3NT in the cerebellum and BA22 in
the autism group (Rose et al., 2012b). Finally, one study of 6
individuals with non-syndromic autism and 6 controls exam-
ined brain tissue from the superior temporal gyrus (BA 41/42
or 22) and reported a 3-fold higher level of oxidative damage to
mitochondrial proteins in the autism group compared to controls
(Palmieri et al., 2010).
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Other studies have documented increased oxidation of DNA
in the brain tissue of individuals with ASD. In one study of 20
individuals with autism and 25 controls, 8-oxo-deoxyguanosine
was elevated in the temporal lobe of the autism group (Tang
et al., 2013). In another study of 8 individuals with autism
and 7 controls, the levels of 8-hydroxydeoxyguanosine were 63%
higher in the cerebellum of the autism group (p = 0.23) (Sajdel-
Sulkowska et al., 2009). Another study of 15 individuals with
autism and 15 controls reported significant elevations in 8-oxo-
deoxyguanosine in the cerebellum and BA22 (superior temporal
lobe) in the autism group. In this study, DNA damage was found
to significantly correlate with the GSH/GSSG redox ratio (Rose
et al., 2012b). However, a study of 10 individuals with autism
(ages 4–30 years) and 10 age- and sex-matched controls reported
similar 8-hydroxyguanosine, a marker of oxidative damage to
RNA, in the frontal cortex (BA 9, 22, 41, 42, or 46) (Muratore
et al., 2013).
Overall, as reviewed above, there are many lines of evidence
supporting the notion of increased levels of oxidative stress in
key regions of the brain in individuals with ASD. First, oxidative
damage to many cellular elements has been reported. Three stud-
ies have reported biomarkers of oxidative damage to lipids in five
brain areas: temporal (López-Hurtado and Prieto, 2008; Chauhan
et al., 2011), parietal (Evans et al., 2008; López-Hurtado and
Prieto, 2008), frontal lobes (López-Hurtado and Prieto, 2008),
hippocampus (Evans et al., 2008), and cerebellum (Evans et al.,
2008; Chauhan et al., 2011). Biomarkers of oxidative damage
to proteins have been reported in four brain areas in 4 stud-
ies: the cerebellum (Sajdel-Sulkowska et al., 2008, 2011; Rose
et al., 2012b), frontal (Sajdel-Sulkowska et al., 2011), temporal
lobes (Palmieri et al., 2010; Sajdel-Sulkowska et al., 2011; Rose
et al., 2012b), and the brainstem (Sajdel-Sulkowska et al., 2011).
Biomarkers of oxidative damage to DNA have been reported in
two areas of the brain in 3 studies: the temporal lobe (Rose et al.,
2012b; Tang et al., 2013) and cerebellum (Sajdel-Sulkowska et al.,
2009).
Secondly, biomarkers indicative of increased reactive oxygen
species have been reported. Abnormal levels of glutathione (low
reduced glutathione, elevated oxidized glutathione and depressed
glutathione redox ratio) have been found in two brain areas in 2
studies: the temporal cortex (Chauhan et al., 2012a; Rose et al.,
2012b) and cerebellum (Rose et al., 2012b), and in one study
a response to oxidative stress (increased heme oxygenase-1) has
been reported in the parietal and frontal lobes and the cerebellum
(Evans et al., 2008).
Lastly, two studies have demonstrated that certain essential
enzymes involved in controlling reactive oxygen species and pro-
ducing glutathione are reduced in three brain areas, including the
temporal lobe (Tang et al., 2013), cerebellum (Tang et al., 2013),
and frontal cortex (Muratore et al., 2013).
Despite this converging evidence of oxidative stress in several
brain areas in multiple studies, it is clear that there are several
limitations to this evidence. First, because of the limited num-
ber of brain tissue samples generally available, the majority of
studies have only examined a limited number of brain samples
(one study only used 2 samples in each group). Thus, although
most studies have included a brain sample from the temporal
area or cerebellum, specific areas of the brain were not consis-
tently analyzed across studies. However, because many of these
studies demonstrate significant effects despite small sample sizes,
the effects found are rather robust across ASD subjects and brain
regions. This raises the possibility that these processes are per-
vasive in ASD. Since it is well accepted that the general ASD
population is composed of heterogeneous phenotypes, larger
samples sizes are needed to determine if subgroups of children
with ASD exist who have significant differences in brain redox
environments.
Still, there are larger questions that must be answered beyond
confirming the notion that oxidative stress is present in the brain
of children with ASD. For example, it is possible that the reduced
transportation of folate into the brain as a consequence of the
folate receptor alpha autoantibody or mitochondrial dysfunc-
tion could reduce the function of methylation and glutathione
metabolism specifically within the brain leading to some of the
findings described above (Frye et al., 2013c). However, many of
these same findings reported for the brain (oxidative damage
to lipids, protein and DNA, glutathione abnormalities, reduced
function of enzymes essential for regulating oxidative stress) have
been found in the blood, immune cells and cell lines derived from
individuals with ASD, thereby raising the question of whether
these findings are specific for the brain or whether they represent
a more general process (Frye et al., 2013c; Frye and James, 2014).
Lastly, the etiology of these abnormalities is not clear, as both
increases in pro-oxidant influences and reductions in antioxi-
dant defenses have both been associated with ASD (Chauhan and
Chauhan, 2006) and it is clear that there are no simple genetic
abnormalities that account for these findings (Frustaci et al., 2012;
Frye and James, 2014).
STUDIES OF MITOCHONDRIAL DYSFUNCTION IN THE ASD
BRAIN
Evidence of mitochondrial dysfunction in the brain of individuals
with autism has been reported by usingmagnetic resonance imag-
ing techniques. Other studies have examined postmortem brain
samples from individuals with ASD compared to controls. Such
studies have demonstrated decreases in electron transport chain
(ETC) complex and tricarboxylic acid (TCA) cycle enzyme activ-
ities, as well as differences in mitochondrial gene expression in
the brain tissue of individuals with autism compared to controls
(Table 2).
The first study to report evidence of mitochondrial dysfunc-
tion in the brain in individuals with ASD was a study of 11
ASD individuals and 11 typically developing (TD) controls which
reported abnormal levels of brain markers of mitochondrial
function in the dorsal prefrontal cortex measured by Phosphorus-
31 magnetic resonance spectroscopy (MRS) (including phos-
phocreatine, αATP, α-adenosine diphosphate, dinucleotides and
diphosphosugars) that significantly correlated with the severity
of language and neuropsychological deficits in the ASD group
but not in the control group (Minshew et al., 1993). Recent
studies have demonstrated that Phosphorus-31 MRS is sensi-
tive in detecting metabolic disturbances in children with mito-
chondrial dysfunction and ASD when muscle and/or brain is
examined (Golomb et al., 2014). Most MRS studies have not
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Table 2 | Studies of mitochondrial dysfunction in the ASD brain.
Year Citation No. of No. of Major findings
published ASD controls
1993 Minshew et al., 1993 11 11 Markers of mitochondrial function were abnormal in ASD brain and correlated
with ASD behaviors
1999 Chugani et al., 1999 9 5 Elevated lactate in the frontal lobe of 1 out of 9 children with ASD; NAA was
reduced in the cerebellum of the ASD group
2003 Friedman et al., 2003 45 28 No significant difference in mean lactate in ASD and control groups
2010 Palmieri et al., 2010 6 6 Higher level of oxidative damage to mitochondrial proteins in BA41/42 or BA22
in ASD group; complex IV activity higher in ASD group
2011 Chauhan et al., 2011 8 8 Lower ETC complex activities in cerebellum, frontal lobe and temporal lobe in
ASD group
2012 Anitha et al., 2012 8 10 Decreased expression of mitochondrial genes in anterior cingulate gyrus, motor
cortex and thalamus in ASD group
2012 Corrigan et al., 2012 54 76 No significant difference in mean lactate in ASD and control groups
2012 Ginsberg et al., 2012 9 9 Decreased ETC complex gene expression in cerebellum and BA19 in ASD
group
2012 Rose et al., 2012b 15 15 Significantly decreased aconitase activity in cerebellum and BA22 in ASD group
2013 Anitha et al., 2013 8 10 Reduced expression of ETC genes (complexes I, III, IV, and V) in the anterior
cingulate gyrus, thalamus, and motor cortex in ASD group
2103 Golomb et al., 2014 6 6 Brain phosphocreatine reduced in muscle and frontal cortex in children with
mitochondrial dysfunction and ASD
2013 Gu et al., 2013a 14 12 Reduced ETC complex I and V activities in frontal lobe in ASD group; a higher
mtDNA copy number compared to nuclear DNA in 3 different mitochondrial
genes found in ASD group
2013 Tang et al., 2013 20 25 Decreased ETC complex I and IV activities in BA21 in ASD group; higher levels
of mitochondrial fission proteins and lower levels of mitochondrial fusion
proteins in BA21 of ASD group
used Phosphorus-31 imaging but have concentrated on the more
popular proton MRS (1H-MRS) technique. The results of 1H-
MRS studies are variable in ASD. However, consistent results
have been reported for the metabolite N-acetyl-aspartate (NAA).
Indeed, studies have consistently demonstrated a decrease in NAA
in global white and gray matter of the brain in children with
ASD, and in the gray matter of the parietal cortex, the cere-
bellum, and the anterior cingulate cortex in both children and
adults with ASD (Ipser et al., 2012). Other investigators have
recently suggested that some of these age-specific changes in
gray matter NAA may be different in ASD children compared
to TD and developmentally delayed children (Corrigan et al.,
2013). NAA is a particularly important brain metabolite as it
is not only a marker of neuronal integrity, but a marker of
mitochondrial dysfunction (Clark, 1998) since it is exclusively
synthesized by the mitochondria of neurons. One study used
MRS to measure NAA and lactate in 9 children with ASD and
5 control siblings in the frontal, temporal and cerebellar areas.
An elevation in lactate was found in the frontal lobe of one
of the 9 children (11%) with ASD, and NAA was reduced in
the cerebellum of the ASD group as compared to the control
group (Chugani et al., 1999). Another study of 45 children with
ASD, 15 children with developmental delay and 13 TD children
reported reduced NAA concentrations in the ASD group com-
pared to the TD controls, but no significant difference in mean
lactate levels (Friedman et al., 2003). A more recent study of 54
children with ASD, 22 children with developmental delay and
54 TD children found no significant difference in mean lactate
levels between groups using 1H-MRS (Corrigan et al., 2012).
Although elevations in lactate have been investigated using 1H-
MRS in children with ASD, it is likely that the lack of findings
in this population is due to the poor sensitivity of 1H-MRS for
identifying lactate elevations in the brain (Rossignol and Frye,
2012c).
Several studies have examined ETC function in the brain of
children with ASD. One study examined 8 children with autism
and 8 controls (4–10 years of age) and reported significantly
lower ETC complex activities in the cerebellum, frontal cortex
and temporal cortex of the autism group (Chauhan et al., 2011).
In another study of temporal lobe brain samples (BA 21) taken
from 20 individuals with autism and 25 controls, there were
decreased ETC complex I and IV activities and protein content
in the ASD group (Tang et al., 2013). In one study of 15 indi-
viduals with ASD and 15 controls, the mean activity of the TCA
cycle enzyme aconitase was significantly decreased in the cerebel-
lum and temporal lobe (BA22) in the autism group (Rose et al.,
2012b). Finally, another study of 14 individuals with autism and
12 controls reported mean reductions in ETC complexes I (31%)
andV (36%) activities as well as in pyruvate dehydrogenase (35%)
in the frontal cortex in the autism group. This study also reported
a higher mitochondrial DNA (mtDNA) copy number compared
to nuclear DNA in 3 different mitochondrial genes in the autism
group; these latter findings might be related to mitochondrial
proliferation (Gu et al., 2013a).
www.frontiersin.org April 2014 | Volume 5 | Article 150 | 5
Rossignol and Frye Physiological abnormalities in autism brain
Several studies have examined changes in the expression of
mitochondrial genes in brain samples of individuals with autism.
Decreased mitochondrial ETC complex gene expression was
found in the cerebellum and BA19 (occipital) brain tissue from
9 individuals with autism compared to 9 controls (Ginsberg et al.,
2012). In another study, reduced expression of mitochondrial
ETC genes, including 11 genes of complex I, five genes of complex
III, five genes of complex IV, and seven genes of complex V were
reported in the anterior cingulate gyrus, thalamus, and motor
cortex derived from 8 patients with autism compared to 10 con-
trols (Anitha et al., 2013). Other studies have examined non-ETC
mitochondrial gene expression in brain tissue from individuals
with autism. For example, decreased expression of mitochon-
drial genes, including metaxin 2, neurofilament, SLC25A27, light
polypeptide (NEFL) and solute carrier family 25 were found in
8 patients with autism (in the anterior cingulate gyrus, motor
cortex and thalamus) compared to 10 controls (Anitha et al.,
2012).
One study examined changes in proteins that regulate mito-
chondrial dynamics. Higher levels of mitochondrial fission pro-
teins and lower levels of mitochondrial fusion proteins were
found in temporal lobe brain samples (BA 21) from 20 individuals
with autism compared to 25 controls (Tang et al., 2013).
Some studies have implicated an association between mito-
chondrial dysfunction and oxidative stress in the brain tissue of
children with autism by showing that these two problems may
coexist in the same brain tissue samples. For example, in tempo-
ral lobe brain samples (BA 21), decreased mitochondrial function
was found along with increased biomarkers of oxidative dam-
age to DNA and decreased superoxide dismutase 2 activity (Tang
et al., 2013). In another study looking at cerebellum, frontal cor-
tex and temporal cortex in 4–10 year olds, brain tissue markers of
oxidative stress were observed along with reduced ETC complex
activities in the autism group (Chauhan et al., 2011). As previ-
ously mentioned, one study of 6 individuals with non-syndromic
autism and 6 controls reported a higher level of oxidative dam-
age to mitochondrial proteins in the superior temporal gyrus
(BA 41/42 or 22) in the autism group compared to controls.
In this study, cytochrome C oxidase (complex IV) activity was
also higher in the individuals with autism (Palmieri et al., 2010).
Lastly, one study correlated markers of oxidative stress with TCA
enzyme function; aconitase activity was inversely correlated with
GSH/GSSG in the cerebellum and the temporal lobe (BA 22) in
15 individuals with ASD compared to 15 controls (Rose et al.,
2012b).
Overall these studies provide support for mitochondrial dys-
function in the brain of individuals with ASD. MRS studies using
both Phosphorus-31 and 1H techniques have examined energy
metabolites in the brain of individuals with ASD, although many
more studies have used the latter technique. Phosphorus-31 MRS
has found abnormal energy metabolites in the frontal cortex
(Minshew et al., 1993; Golomb et al., 2014) while 1H-MRS has
found a reduction in NAA in the global white and gray matter and
the parietal, anterior cingulate and cerebellum areas (Ipser et al.,
2012). ETC function has been reported to be depressed in frontal
(Chauhan et al., 2011), temporal (Chauhan et al., 2011; Tang
et al., 2013), and cerebellar (Chauhan et al., 2011) brain tissue
derived from individuals with ASD, with ETC complex I most
commonly reported depressed. Other studies noted decreases in
the activity of non-ETCmitochondrial enzymes (aconitase, pyru-
vate dehydrogenase) in frontal (Gu et al., 2013a), temporal (Rose
et al., 2012b), and cerebellar (Rose et al., 2012b) tissue derived
from children with ASD. Depressed expression of ETC genes in
the occipital and cerebellar areas and of ETC and non-ETC genes
in the cingulate, thalamus and frontal areas have been reported
(Anitha et al., 2013). In addition, changes in genes that control
mitochondrial dynamics have been noted in the temporal lobe
(Tang et al., 2013).
As with studies on oxidative stress, studies of mitochondrial
function in the brain of individuals with ASD are mostly based
on small numbers of samples, involve a wide variety of meth-
ods, and study various regions of the brain without consistency
across studies. Despite these limitations, these studies demon-
strate that mitochondrial dysfunction is consistently found in
the brain of individuals with ASD. The studies on ETC func-
tion are consistent with studies performed on muscle tissue as
both demonstrate ETC complex I deficiency as the most prevalent
ETC complex abnormality (Rossignol and Frye, 2012b). Several
studies have provided powerful evidence for the correspondence
between oxidative stress and mitochondrial dysfunction in the
same brain samples (Chauhan et al., 2011; Rose et al., 2012b;
Tang et al., 2013). This is one step forward to understanding the
interaction between oxidative stress and mitochondrial dysfunc-
tion. Future studies could make such evidence more powerful by
correlating these abnormalities with peripheral markers of mito-
chondrial dysfunction and oxidative stress as well as examining
clinical characteristics.
STUDIES OF INFLAMMATION AND IMMUNE
DYSREGULATION IN THE ASD BRAIN
Inflammation and immune dysregulation have been observed in
both brain tissue and cerebrospinal fluid (CSF) samples from
individuals with ASD. In brain tissue, increases in cytokines,
expression in immune-related genes, microglial cell activation
and other biomarkers of inflammation have also been reported
(Table 3).
While some studies have reportedmicroglial activation in indi-
viduals with autism compared to controls, others have studied
differences in the spatial organization of microglial cells in indi-
viduals with autism. Microglia are immune cells in the CNS
which are activated to eliminate damaged cells or infectious
agents through the process of phagocytosis. However, when the
microglia are chronically activated, they may increase inflamma-
tion through the release of proinflammatory cytokines and free
radicals (Dheen et al., 2007). The first study to examine microglia
in ASD reported significant activation of microglia and reactive
astroglia in the middle frontal gyrus, anterior cingulate gyrus and
cerebellum in 11 patients with autism compared to 6 controls
(Vargas et al., 2005). The second study examined the dorsolat-
eral prefrontal cortex in 13 males with autism and 9 controls
and reported marked microglial activation in 5 out of the 13
autism cases (38.5%) and mild microglial activation in another
4 cases (30.8%) (Morgan et al., 2010). Finally, one study of 20
men with autism and 20 age- and IQ-matched controls reported
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Table 3 | Studies of inflammation/immune dysregulation in the ASD brain.
Year Citation No. of No. of Major findings
published ASD controls
2005 Vargas et al., 2005 11 6 Activation of microglia and astroglia in the middle frontal gyrus, anterior
cingulate gyrus and cerebellum in ASD group; anti-inflammatory cytokine tumor
growth factor–1 and pro-inflammatory macrophage chemoattractant protein-1
were increased in these areas in ASD group; IFN-gamma, MCP-1, TGF-beta2,
and IL-8 increased in CSF of ASD group
2005 Zimmerman et al., 2005 12 27 CSF quinolinic acid and neopterin were significantly lower and biopterin was
significantly elevated in ASD group
2007 Chez et al., 2007 10 0 Elevated TNF-alpha concentration in CSF compared to serum levels
2008 Garbett et al., 2008 6 6 Increased transcription levels of several immune-related genes in the superior
temporal gyrus in ASD group
2008 López-Hurtado and Prieto, 2008 8 7 Reactive gliosis in BA22, BA44, and BA39 in ASD group
2009 Li et al., 2009 8 8 Elevated proinflammatory cytokines in frontal cortex in ASD group
2010 Morgan et al., 2010 13 9 Microglial activation found in dorsolateral prefrontal cortex in ASD group
2011 Malik et al., 2011b 7 7 No significant difference in NF-KappaB expression in the cerebellum and frontal
cortex between ASD and controls
2011 Wei et al., 2011 6 6 Elevated IL-6 in cerebellum in ASD group
2011 Young et al., 2011 9 9 NF-KappaB expression in the orbitofrontal cortex was increased in ASD group
2012 Rose et al., 2012b 15 15 Elevated 3-chlorotyrosine level in the cerebellum and temporal cortex in the
ASD group
2013 Suzuki et al., 2013 20 20 Microglial activation in multiple brain regions in ASD group
evidence of microglial activation using positron emission tomog-
raphy in multiple brain regions (cerebellum, brainstem, corpus
callosum, fusiform gyri, superior temporal gyri, anterior cingu-
late, orbitofrontal, and parietal lobes) in the autism group (Suzuki
et al., 2013).
Other studies have noted differences in microglial spatial orga-
nization on the microscopic andmacroscopic levels in individuals
with ASD. One study reported that microglia in the dorsolat-
eral prefrontal cortex were frequently located closer to neurons
in 13 individuals with autism compared to 9 controls (Morgan
et al., 2012a), while another study reported that microglial cells
were associated with reactive astrocytes in 11 patients with autism
(Vargas et al., 2005). Another study examined microglia from the
fronto-insular and visual cortex in 11 individuals with autism
and 12 controls and reported significantly more microglia in the
fronto-insular cortex in the autism group; however, this study did
not examine microglial activation (Tetreault et al., 2012). Reactive
gliosis has been reported in association with microglia activation
in one study of 11 patients with autism (Vargas et al., 2005), while
another study of 8 males with autism and 7 male controls sug-
gested reactive gliosis along with a greater density of glial cells in
3 different brain areas associated with language (BA 22: speech
recognition; BA 44: speech production; and BA 39: reading) in
the autism group (López-Hurtado and Prieto, 2008).
Several studies have described increased proinflammatory
cytokines in brain tissue from individuals with ASD. One study
reported elevations in proinflammatory cytokines (including
TNF-alpha, IL-6 and GM-CSF), a Th1 cytokine (IFN-gamma)
and a chemokine (IL-8) measured in postmortem frontal cor-
tex brain samples from 8 individuals with autism compared
to 8 controls, but no significant differences in Th2 cytokines
(IL-4, IL-5, and IL-10) (Li et al., 2009). Another study reported
that IL-6 was significantly increased in the cerebellum of 6
children with autism compared to 6 age-matched control chil-
dren (Wei et al., 2011). In a study of 11 patients with autism,
both anti-inflammatory cytokine tumor growth factor-1 and
pro-inflammatory macrophage chemoattractant protein-1 were
found to be increased in the middle frontal gyrus, ante-
rior cingulate gyrus and cerebellum. Other pro-inflammatory
and modulatory cytokines, including interleukin-6 (IL-6), IL-
10, MCP-3, eotaxin, eotaxin 2, macrophage-derived chemokine
(MDC), chemokine-8 (Ck-8.1), neutrophil activating peptide-2
(NAP-2), monokine induced by interferon (MIG), B-lymphocyte
chemoattractant (BLC), leptin and osteoprotegerin, were only
consistently elevated in the anterior cingulate gyrus (Vargas et al.,
2005).
Other studies have examined the expression of inflamma-
tory genes in brain tissue of individuals with autism. One study
reported increased transcription levels of several immune-related
genes in the superior temporal gyrus of 6 individuals with autism
compared to 6 controls, consistent with neuroimmune activa-
tion (Garbett et al., 2008). Two studies examined the NF-KappaB
pathway in the brains of individuals with autism. One study
reported that NF-KappaB expression in the orbitofrontal cortex
was increased in 9 individuals with autism compared to 9 con-
trols (Young et al., 2011). Another study of 7 individuals with
autism and 7 controls reported no significant difference in NF-
KappaB expression in the cerebellum and frontal cortex (Malik
et al., 2011b).
One study of 15 individuals with ASD and 15 controls
reported elevated 3-chlorotyrosine levels, a biomarker of chronic
inflammation, in the cerebellum and temporal cortex in the
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ASD group, along with increased markers of oxidative stress and
mitochondrial dysfunction (Rose et al., 2012b).
Several studies examined cytokines and other inflammatory
markers in the CSF of individuals with ASD. The first study to
report findings related to inflammation in the CSF of patients
with autism reported significantly elevated IFN-gamma, MCP-
1, TGF-beta2, and IL-8 in 6 children with autism compared to 9
child and adult controls (Vargas et al., 2005). One uncontrolled
study of 10 children with autism who had a history of regres-
sion in language and eye contact examined CSF for inflammatory
changes. In this case series, the mean TNF-alpha concentration
in CSF was 104.10 pg/mL compared to concurrent serum levels
of 2.78 pg/mL (Chez et al., 2007), suggesting production of TNF-
alpha in the CNS rather than from systematic inflammation or
inflammation of a peripheral tissue. Lastly, one study did not find
evidence of immune dysregulation in the CSF in individuals with
ASD. In this study of 12 children with autism and 27 controls with
other neurological disorders, CSF quinolinic acid and neopterin
were significantly lower and biopterin was significantly elevated
in the autism group (Zimmerman et al., 2005).
The evidence reviewed above clearly supports the notion that
there are alterations in the immune system upon examination of
the brain in individuals with ASD. The strongest evidence for acti-
vation of the immune system are the studies which demonstrated
histological evidence of microglia cell changes in the frontal
(Vargas et al., 2005; Morgan et al., 2010, 2012a; Tetreault et al.,
2012), cingulate (Vargas et al., 2005) and cerebellum (Vargas et al.,
2005). Neuroimaging supports these histological findings (Suzuki
et al., 2013). Evidence for disruption in immune regulation is
supported by elevations in proinflammatory cytokines in brain
tissue from the frontal (Li et al., 2009), cingulate (Vargas et al.,
2005), and cerebellum (Wei et al., 2011) and in CSF (Vargas et al.,
2005; Chez et al., 2007) derived from individuals with ASD and
elevations in the expression of genes regulating proinflammatory
pathways in the temporal (Garbett et al., 2008) and frontal (Young
et al., 2011) areas in individuals with ASD. Although some stud-
ies have reported some negative or inconsistent results (Vargas
et al., 2005; Zimmerman et al., 2005; Malik et al., 2011b), the
majority of studies point to an activation of the innate immune
system in the brain of individuals with ASD and some of the
findings, particularly the cytokine elevations, parallel abnormal
elevations in cytokines reported in non-CNS tissue in children
with ASD. Although these studies suffer from small sample sizes
and inconsistency in brain areas examined, together they pro-
vide support for more comprehensive research into the role of
inflammation and immune dysregulation in the brain of children
with ASD.
DISCUSSION
Although ASD is defined by observations of behaviors and is thus
classified as a psychiatric disorder, recent evidence has pointed
to physiological abnormalities in ASD, suggesting that ASD has a
clear biological basis with features of known medical disorders. A
number of studies using peripheral biomarkers have linked oxida-
tive stress, mitochondrial dysfunction and immune dysregulation
in individuals with ASD (James et al., 2009a; Mostafa et al., 2010;
Zhang et al., 2010; Napoli et al., 2013; Theoharides et al., 2013;
Frye et al., 2013a). Recently, studies have examined possible inter-
actions between these abnormalities in the brain of individuals
with ASD. Indeed, many of the reviewed studies have been pub-
lished since 2010, including studies examining oxidative stress
(8/12 studies, 67%), mitochondrial dysfunction (11/13, 85%) and
immune abnormalities (8/14, 57%).
Furthermore, four studies reported that oxidative stress and
mitochondrial dysfunction were linked in the brain of individu-
als with ASD (Palmieri et al., 2010; Chauhan et al., 2011; Rose
et al., 2012b; Tang et al., 2013), whereas two studies reported
a connection between oxidative stress and inflammation in the
brain (López-Hurtado and Prieto, 2008; Rose et al., 2012b). One
of these studies linked low GSH levels, oxidative stress, mitochon-
drial dysfunction and inflammation in the brain of individuals
with ASD (Rose et al., 2012b). Interestingly, only one study
reported no evidence of inflammation in the CSF of individu-
als with ASD (Zimmerman et al., 2005), whereas another study
found a similar oxidative stress marker in both groups, although
several findings suggestive of an adaptive response to oxidative
stress were observed in the brains of individuals with autism
(Muratore et al., 2013).
A recent systematic review of 112 individuals with ASD
and concomitant mitochondrial disease found that only about
21% had a genetic abnormality that could account for the
reported mitochondrial problem (Rossignol and Frye, 2012a).
Mitochondrial dysfunction found in some individuals with
autism could be related to inflammation or immune dysregula-
tion. For example, TNF-alpha is known to inhibit mitochondrial
function (Suematsu et al., 2003; Vempati et al., 2007; Samavati
et al., 2008) and elevations in TNF-alpha, from individuals with
ASD compared to controls, have been reported in lymphocytes
(Malik et al., 2011a), amniotic fluid (Abdallah et al., 2013), CSF
(Chez et al., 2007) and brain samples (Li et al., 2009). GSH
protects mitochondria against the adverse effects of TNF-alpha
(Fernandez-Checa et al., 1997) and GSH deficiency can lead to
impaired mitochondrial function (Vali et al., 2007). Interestingly,
TNF-alpha (also known as cachexin) is known to decrease mito-
chondrial enzymatic function, including cytochrome c oxidase
(complex IV) activity (Remels et al., 2010). Some studies, includ-
ing one using brain tissue, have reported complex IV overactivity
in individuals with ASD rather than an inhibition of this com-
plex (Palmieri et al., 2010; Frye and Naviaux, 2011). It may be
that active inflammation results in a compensatory increase in
complex IV activity so that this complex becomes overactive once
the inflammation has subsided (Frye and Naviaux, 2011); such
a scenario could explain why complex IV is found to be both
reduced and increased in multiple sclerosis lesions depending
upon whether the lesion is undergoing active inflammation or
whether the inflammation has subsided (Lu et al., 2000; Mahad
et al., 2009).
In addition, oxidative stress may lead to impaired mitochon-
drial function (Fernandez-Checa et al., 1997). For example, the
mitochondrial ETC is the predominant source and major tar-
get of free radicals (Fernandez-Checa et al., 1998; Trushina and
McMurray, 2007). Free radicals impair mitochondrial function
(Fernandez-Checa et al., 1997; Wallace, 1999). Mitochondria are
protected from oxidative stress by GSH (Fernandez-Checa et al.,
Frontiers in Physiology | Mitochondrial Research April 2014 | Volume 5 | Article 150 | 8
Rossignol and Frye Physiological abnormalities in autism brain
Table 4 | Regions affected along with function/findings; organized by oxidative stress, mitochondrial dysfunction and immune dysregulation.
Region Function Findings in autism compared to controls
CSF Immune dysregulation:
• Elevated INF-gamma, MCP-1, TGF-beta2, and IL-8 (Vargas et al., 2005)
• Elevated TNF-alpha concentration (Chez et al., 2007)
• CSF quinolinic acid and neopterin were significantly lower and biopterin was
significantly elevated (Zimmerman et al., 2005)
FRONTAL LOBE
Frontal lobe Motor control and planning, higher cognitive
function, executive function (attention,
working memory, planning, behavioral
control), decision making, thinking
Oxidative stress:
• Similar 8-hydroxyguanosine in the frontal cortex (BA 9, 22, 41, 42, or 46)
between groups. Significantly lower methionine synthase mRNA along with
lower levels of homocysteine and cystathionine is same areas in the autism
brains, suggestive of adaptive responses to oxidative stress (Muratore et al.,
2013)
Mitochondrial dysfunction:
• Elevation in lactate by MRS (Chugani et al., 1999)
• Lower ETC complex activities (Chauhan et al., 2011) with mean reductions in
ETC complexes I (31%) and V (36%) activities (Gu et al., 2013a)
• A higher mitochondrial DNA (mtDNA) copy number (Gu et al., 2013a)
Immune dysregulation:
• Elevations in proinflammatory cytokines (including TNF-alpha, IL-6 and
GM-CSF), a Th1 cytokine (IFN-gamma) and a chemokine (IL-8) (Li et al., 2009)
Middle frontal gyrus Lexical and semantic processing,
comprehension
Immune dysregulation:
• Activation of microglia and astroglia (Vargas et al., 2005)
• Anti-inflammatory cytokine tumor growth factor–1 and pro-inflammatory
macrophage chemoattractant protein-1 were found to be increased (Vargas
et al., 2005)
Dorsal prefrontal
cortex
Working memory, planning, behavioral
regulation, reasoning
Mitochondrial dysfunction:
• Abnormal levels of brain markers of mitochondrial function by MRS (Minshew
et al., 1993)
Immune dysregulation:
• Microglial activation (Morgan et al., 2010)
BA11 (Orbitofrontal
cortex)
Emotion, reward, expectations Oxidative stress:
• Elevated 3NT levels (Sajdel-Sulkowska et al., 2011)
Immune dysregulation:
• Activation of microglia (Suzuki et al., 2013)
• NF-KappaB expression was increased (Young et al., 2011)
BA44 (Broca’s area
in dominant
hemisphere)
Response inhibition, music perception,
speech production in the dominant
hemisphere
Oxidative stress:
• Increase in lipofuscin-containing cells (López-Hurtado and Prieto, 2008)
Immune dysregulation:
• Reactive gliosis (López-Hurtado and Prieto, 2008)
PARIETAL LOBE
Parietal lobes Immune dysregulation:
• Activation of microglia (Suzuki et al., 2013)
BA39 (gyrus
angularis)
Reading Oxidative stress:
• Increase in lipofuscin-containing cells (López-Hurtado and Prieto, 2008)
• Elevated markers of oxidative damage (Evans et al., 2008)
Immune dysregulation:
• Reactive gliosis (López-Hurtado and Prieto, 2008)
TEMPORAL LOBES
Temporal lobes Oxidative stress:
• Lowered GSH and GSH/GSSG (Chauhan et al., 2012a)
(Continued)
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Table 4 | Continued
Region Function Findings in autism compared to controls
• Higher levels of lipid hydroperoxides (Chauhan et al., 2011)
• 8-oxo-deoxyguanosine higher (Tang et al., 2013)
Mitochondrial dysfunction:
• Lower ETC complex activities (Chauhan et al., 2011)
Immune dysregulation:
• Elevated 3-chlorotyrosine (Rose et al., 2012b)
Superior temporal
gyrus
Primary auditory cortex and recognition of
sound and language (in the dominant
hemisphere)
Immune dysregulation:
• Microglial activation (Suzuki et al., 2013)
• Increased transcription levels of several immune-related genes (Garbett et al.,
2008)
Hippocampus Long term memory Oxidative stress:
• Elevated markers of oxidative damage (Evans et al., 2008)
BA21 Processing of sound and language (in
dominant hemisphere)
Oxidative stress:
• Decreased superoxide dismutase 2 activity (Tang et al., 2013)
Mitochondrial dysfunction:
• Decreased ETC complex I and IV activities (Tang et al., 2013)
• Higher levels of mitochondrial fission proteins and lower levels of
mitochondrial fusion proteins (Tang et al., 2013)
BA22 (Wernicke’s
area in dominant
hemisphere)
Speech processing and understanding in
dominant hemisphere
Oxidative stress:
• Lowered GSH and GSH/GSSG (Rose et al., 2012b)
• Increase in lipofuscin-containing cells (López-Hurtado and Prieto, 2008)
• Elevated 3NT levels (Sajdel-Sulkowska et al., 2011; Rose et al., 2012b)
• 3-fold higher level of oxidative damage to mitochondrial proteins (Palmieri
et al., 2010)
• Significant elevations in 8-oxo-deoxyguanosine (Rose et al., 2012b)
Mitochondrial dysfunction:
• Mean activity of the TCA cycle enzyme aconitase was significantly decreased
(Rose et al., 2012b)
Immune dysregulation:
• Reactive gliosis (López-Hurtado and Prieto, 2008)
BA41/42 Auditory Oxidative stress:
• 3-fold higher level of oxidative damage to mitochondrial proteins (Palmieri
et al., 2010)
OCCIPITAL LOBE
BA19 (occipital lobe) Visual feature extraction and shape
recognition, visual attention
Mitochondrial dysfunction:
• Decreased mitochondrial ETC complex gene expression (Ginsberg et al., 2012)
CEREBELLUM
Cerebellum Motor coordination, modulation of cognition
and behavior
Oxidative stress:
• Lowered GSH and GSH/GSSG (Chauhan et al., 2012a; Rose et al., 2012b)
• Lowered glutathione peroxidase, glutathione-S-transferase, and glutamate
cysteine ligase (Gu et al., 2013b)
• Elevated markers of oxidative damage (Evans et al., 2008)
• Higher levels of lipid hydroperoxides (Chauhan et al., 2011)
• Elevated 3-NT (Sajdel-Sulkowska et al., 2008, 2011; Rose et al., 2012b)
• Significant elevations in 8-oxo-deoxyguanosine (Rose et al., 2012b); trend for
elevation in 8-hydroxydeoxyguanosine (Sajdel-Sulkowska et al., 2009)
Mitochondrial dysfunction:
• Lower ETC complex activities (Chauhan et al., 2011)
• Mean activity of the TCA cycle enzyme aconitase was significantly decreased
(Rose et al., 2012b)
(Continued)
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Table 4 | Continued
Region Function Findings in autism compared to controls
• Decreased mitochondrial ETC complex gene expression (Ginsberg et al., 2012)
Immune dysregulation:
• Activation of microglia (Vargas et al., 2005; Suzuki et al., 2013) and reactive
astroglia (Vargas et al., 2005)
• IL-6 was significantly increased (Wei et al., 2011)
• Anti-inflammatory cytokine tumor growth factor–1 and pro-inflammatory
macrophage chemoattractant protein-1 were found to be increased (Vargas
et al., 2005)
• Elevated 3-chlorotyrosine (Rose et al., 2012b)
LIMBIC SYSTEM
Thalamus Sensory and motor relaying and gating,
cortical rhythm generator
Mitochondrial dysfunction:
• Reduced expression of mitochondrial ETC genes (Anitha et al., 2013)
• Decreased expression of mitochondrial genes (Anitha et al., 2012)
Anterior cingulate
gyrus
Error detection, conflict monitoring,
emotional awareness, pain
Mitochondrial dysfunction:
• Reduced expression of mitochondrial ETC genes (Anitha et al., 2013)
• Decreased expression of mitochondrial genes (Anitha et al., 2012)
Immune dysregulation:
• Activation of microglia (Vargas et al., 2005; Suzuki et al., 2013) and reactive
astroglia (Vargas et al., 2005)
• Anti-inflammatory cytokine tumor growth factor–1 and pro-inflammatory
macrophage chemoattractant protein-1 were found to be increased (Vargas
et al., 2005)
BRAINSTEM
Pons Autonomic function, eye movements, motor
and sensory relay
Oxidative stress:
• Elevated 3NT levels (Sajdel-Sulkowska et al., 2011)
1998), although other antioxidant systems are also important
(such as MnSOD). However, mitochondria lack the enzymes to
produce GSH and are dependent on GSH production in the
cytosol (Enns, 2003; James et al., 2009a), although mitochondria
do possess glutathione reductase and therefore can regenerate
GSH from GSSG. Depletion of GSH can lead to mitochondrial
impairment and make cells more vulnerable to damage from
free radicals which originate in the mitochondria (Fernandez-
Checa et al., 1997). Several studies have reported lower GSH
levels (James et al., 2004, 2006, 2009b) along with a lower
mitochondrial GSH reserve (James et al., 2009a) in individu-
als with ASD compared to controls. Oxidative stress appears
to be a common feature in individuals with ASD (Chauhan
and Chauhan, 2006; Frustaci et al., 2012) and may play a
role in the mitochondrial dysfunction reported in some chil-
dren with ASD (Frye and Rossignol, 2011; Rossignol and Frye,
2012b).
A number of studies have reported that biomarkers of oxida-
tive stress, mitochondrial dysfunction and immune dysregulation
are correlated with autism severity. While none of the stud-
ies examining brain tissue in autism correlated findings with
autism severity, some studies reported that brain areas affected by
oxidative stress, mitochondrial dysfunction and immune dysreg-
ulation are areas responsible for brain functions that are typically
impaired in ASD (Table 4). For example, areas involved in speech
processing (Sajdel-Sulkowska et al., 2011; Rose et al., 2012b),
memory, social interaction, and sensory and motor coordination
(Sajdel-Sulkowska et al., 2011) were reported as having oxidative
stress in some studies. Therefore, some of these physiological
abnormalities in the brain may account for certain symptoms
of autism. It is possible that treatment of these abnormalities
may lead to a reduction in autism behaviors. For example, a
number of studies have reported improvements in autism using
nutritional supplements and medications which can support
mitochondrial function (Geier et al., 2011; Frye and Rossignol,
2012b; Rossignol and Frye, 2012b; Fahmy et al., 2013), reduce
oxidative stress (Dolske et al., 1993; Chez et al., 2002; Adams and
Holloway, 2004; Rossignol, 2009; Adams et al., 2011; Rossignol
and Frye, 2011; Hardan et al., 2012; Ghanizadeh and Moghimi-
Sarani, 2013), and decrease inflammation (Stefanatos et al., 1995;
Shenoy et al., 2000; Boris et al., 2007; Bradstreet et al., 2007;
Asadabadi et al., 2013; Taliou et al., 2013). Additional stud-
ies are needed to determine if these types of treatments lead
to changes in oxidative stress, mitochondrial dysfunction and
immune abnormalities reported in the brains of some individuals
with ASD.
CONCLUSIONS AND PERSPECTIVES
Overall, the studies reviewed above provide support for the idea
that oxidative stress, mitochondrial dysfunction and inflamma-
tion/immune dysfunction, which are physiological abnormalities
identified in non-CNS tissue in children with ASD, are also found
to affect the CNS. A few studies demonstrated the connection
between these physiological abnormalities. However, there were
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several limitations to the studies reviewed, including small sample
sizes and inconsistencies in the techniques and biomarkers stud-
ied and the brain areas examined. Because of these limitations, at
this time, it is difficult to know if the findings are localized to a
certain portion of the brain or whether these abnormalities are
more diffuse. Another challenge is whether or not these abnor-
malities can be generalized to all children with ASD, or if they
represent a subgroup of children with ASD. However, the consis-
tent positive findings across studies suggest that these effects are
not subtle and may be important in the pathological mechanisms
that disrupt brain function in ASD.
Of interest is that many of the physiological abnormalities
noted in the brain of children with ASD are also found in vari-
ous other neurocognitive and psychiatric diseases. For example,
studies in both Alzheimer and Parkinson disease have impli-
cated dysfunction of ETC function (primarily complex IV in
Alzheimer and primarily complex I in Parkinson) and in the
dynamics of mitochondrial fission and fusion (Moran et al.,
2012b), two specific mitochondrial abnormalities that have been
reported in ASD. Interestingly, the mitochondria is being investi-
gated for its role in axonal degeneration and repair in multiple
sclerosis (van Horssen et al., 2012). Along with mitochondrial
dysfunction, oxidative stress and inflammation have also been
implicated in a wide range of neurodegenerative diseases includ-
ing Alzheimer, Parkinson, multiple sclerosis, amyotrophic lateral
sclerosis and Friedreich’s ataxia (Calabrese et al., 2005; Nuzzo
et al., 2013). Like ASD, inflammation, oxidative stress and mito-
chondrial dysfunction are seen in a wide range of psychiatric
disorders (Dantzer et al., 2008; Ng et al., 2008; Shao et al.,
2008; Burke and Miller, 2011). Thus, these pathophysiological
mechanisms appear to be shared by many diseases that have
cognitive and behavioral symptoms. Therefore, future research
will need to investigate which pathophysiological mechanisms are
shared among these diseases. Such knowledge may lead to novel
treatments and strategies for preventing these pathophysiological
processes, and thus neurocognitive and psychiatric diseases, from
developing.
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